Related Experiment Video

Updated: Aug 10, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

vWf levels as a circulating marker of endothelial dysfunction in patients with hypertrophic cardiomyopathy

Ercan Varol1, Mehmet Ozaydin, Mehmet Sahin

  • 1Department of Cardiology, Isparta State Hospital, Suleyman Demirel University, Turkey. drercanvarol@yahoo.com

Indian Heart Journal
|March 9, 2006
PubMed

Insights

Von Willebrand factor levels are not elevated in hypertrophic cardiomyopathy patients and do not correlate with disease severity. This suggests von Willebrand factor is not a reliable biomarker for endothelial dysfunction in this condition.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Biomarkers

Background:

  • Hypertrophic cardiomyopathy (HCM) is a complex cardiac condition.
  • Endothelial dysfunction is implicated in cardiovascular diseases.
  • Von Willebrand factor (vWF) is a potential marker for endothelial dysfunction.

Purpose of the Study:

  • To determine if von Willebrand factor (vWF) levels are increased in patients with hypertrophic cardiomyopathy (HCM).
  • To investigate the relationship between vWF levels and the clinical status (functional class) of HCM patients.

Main Methods:

  • A case-control study involving 29 HCM patients and 29 age- and gender-matched healthy controls.
  • Measurement of plasma von Willebrand factor (vWF) levels in all participants.
  • Comparison of vWF levels between HCM patients and controls, and across different functional classes of HCM.

Main Results:

  • No significant difference was observed in von Willebrand factor (vWF) levels between hypertrophic cardiomyopathy (HCM) patients and healthy controls.
  • Von Willebrand factor (vWF) levels did not differ significantly between HCM patients in functional class I/II and those in functional class III.
  • No correlation was found between vWF levels and the functional class of HCM patients.

Conclusions:

  • Von Willebrand factor (vWF) levels are not elevated in patients with hypertrophic cardiomyopathy (HCM).
  • Von Willebrand factor (vWF) levels do not correlate with the clinical severity or functional class in HCM patients.
  • vWF is unlikely to be a useful biomarker for endothelial dysfunction in hypertrophic cardiomyopathy (HCM).
Abstract

More Related Videos

Non-invasive Assessment of Microvascular and Endothelial Function05:41

Non-invasive Assessment of Microvascular and Endothelial Function

Published on: January 29, 2013

Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease08:57

Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease

Published on: May 22, 2026

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...